Last reviewed 2026-04-22 · How we verify

Vehicle of Zylet

Bausch & Lomb Incorporated · FDA-approved active Small molecule

Vehicle of Zylet is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists.

The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin.

The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin. Used for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists.

At a glance

Generic name	Vehicle of Zylet
Sponsor	Bausch & Lomb Incorporated
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

Zylet is a combination ophthalmic suspension containing a corticosteroid (loteprednol etabonate) and an aminoglycoside antibiotic (tobramycin). The vehicle itself is not pharmacologically active but is formulated to provide appropriate viscosity, stability, and ocular bioavailability for topical eye drop administration. The vehicle enables sustained contact with ocular tissues and optimal therapeutic delivery of the active agents.

Approved indications

Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists

Common side effects

Ocular irritation
Conjunctival erythema
Increased intraocular pressure

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vehicle of Zylet CI brief — competitive landscape report
Vehicle of Zylet updates RSS · CI watch RSS
Bausch & Lomb Incorporated portfolio CI

Frequently asked questions about Vehicle of Zylet

What is Vehicle of Zylet?

Vehicle of Zylet is a Small molecule drug developed by Bausch & Lomb Incorporated, indicated for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists.

How does Vehicle of Zylet work?

The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin.

What is Vehicle of Zylet used for?

Vehicle of Zylet is indicated for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists.

Who makes Vehicle of Zylet?

Vehicle of Zylet is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).

What development phase is Vehicle of Zylet in?

Vehicle of Zylet is FDA-approved (marketed).

What are the side effects of Vehicle of Zylet?

Common side effects of Vehicle of Zylet include Ocular irritation, Conjunctival erythema, Increased intraocular pressure.

Manufacturer: Bausch & Lomb Incorporated — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists
Compare: Vehicle of Zylet vs similar drugs
Pricing: Vehicle of Zylet cost, discount & access